According to Optimer, Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of Clostridium difficile.
Michael Chang, president and CEO of Optimer, said: “The issuance of this production patent is another important milestone in strengthening the patent estate of our lead product candidate, fidaxomicin. We believe this patent and the issued polymorphic form A patent, along with additional pending patent applications, will enhance our intellectual property protection for fidaxomicin.”